There are 412 resources available
208P - Clinicopathological factors and treatment management in HER2+ breast cancer patients with central nervous system metastasis
Presenter: Ornella Ponzoni
Session: Lunch and Poster Display session
209P - Real-world effectiveness of palbociclib + endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
Presenter: Matthias Korell
Session: Lunch and Poster Display session
210P - Prognostic value of HER2-low status in metastatic breast cancer (mbc) patients treated with I line CDK 4/6 inhibitors (CDK 4/6i): A real-word analysis of the GIM14/BIOMETA study
Presenter: Chiara Molinelli
Session: Lunch and Poster Display session
211P - Drug-drug interactions and their impact on clinical outcomes and adverse events in hormone receptor (HR)+/HER2- advanced breast cancer patients treated with ribociclib + letrozole: Insights from the BioltaLEE trial
Presenter: Andrea Botticelli
Session: Lunch and Poster Display session
212P - A phase Ib/II study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer
Presenter: Virginia Borges
Session: Lunch and Poster Display session
213P - Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC)
Presenter: Stefania Morganti
Session: Lunch and Poster Display session
214P - Comparing ribociclib versus palbociclib as a second-line treatment in combination with fulvestrant in metastatic breast cancer: A randomised clinical trial
Presenter: manar hamed
Session: Lunch and Poster Display session
215P - Impact of germline BRCA1/2 pathogenic variants on outcomes of HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: A systematic review and meta-analysis
Presenter: Michele Bottosso
Session: Lunch and Poster Display session
216P - What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine? Real-world data from the RIBANNA study (6th interim analysis (IA))
Presenter: Diana Luftner
Session: Lunch and Poster Display session
217P - Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicity
Presenter: Chiara Benvenuti
Session: Lunch and Poster Display session